Cohance Lifesciences Limited (NSE:COHANCE)
India
· Delayed Price · Currency is INR 542.55
-6.55 (-1.19%)
At close: Dec 5, 2025
Cohance Lifesciences Revenue
Cohance Lifesciences had revenue of 5.56B INR in the quarter ending September 30, 2025, with 115.57% growth. This brings the company's revenue in the last twelve months to 12.11B, up 25.95% year-over-year. In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B with 13.91% growth.
Revenue (ttm)
12.11B
Revenue Growth
+25.95%
P/S Ratio
17.15
Revenue / Employee
9.99M
Employees
1,212
Market Cap
207.56B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Divi's Laboratories | 100.29B |
| Cipla | 279.66B |
| Apollo Hospitals Enterprise | 232.65B |
| Zydus Lifesciences | 244.94B |
| Mankind Pharma | 135.46B |
| Aurobindo Pharma | 325.14B |
| Fortis Healthcare | 84.37B |